Table 1. Replication of vaccine virus and clinical assessment in adults, RSV-seropositive children, and RSV-seronegative children.

NT, not tested.

					Viral detection (culture)	Viral detection (qPCR)		% with indicated illness*
Subjects	Dose (log₁₀ PFU/ml)	No. of subjects	% Infected	% Shedding virus^†	Peak titer mean (SD) log₁₀ PFU/ml	Peak copy number log₁₀ (SD)	Fever	URI	LRI	Cough	OM	Respiratory or febrile illness	Other
Adults
Vaccinees	6.0	15	0	0	0.6 (0.0)	NT	0	20	0	7	0	20	27
Seropositive children
Vaccinees	6.0	10	10	0	0.6 (0.0)	NT	0	40	0	0	0	40	20
Placebo recipients	Placebo	5	20	0	0.6 (0.0)	NT	0	0	0	0	0	0	60
Seronegative children
Vaccinees	5.0	20	95	85	1.5 (0.9)	3.4 (0.9)	20	85	0	35	5	85	45
Infected placebo recipient^‡	Placebo	1	100	100	2.0 (0.0)	3.3 (0.0)	100	100	0	0	0	100	0
Placebo recipients	Placebo	9	0	0	0.6 (0.0)	1.7 (0.0)	22	44	0	33	0	67	78

*Illness abbreviations and definitions are as described in the text. URI was defined as rhinorrhea, pharyngitis, or hoarseness, and LRI was defined as wheezing, rhonchi, or rales, or having been diagnosed with pneumonia or laryngotracheobronchitis (croup).

†% Shedding vaccine virus as detected by culture and/or rRT-qPCR. The limit of detection of vaccine virus was 0.6 log₁₀ PFU/ml by culture, and 1.7 log₁₀ copy numbers/ml by rRT-qPCR.

‡Data from the seronegative placebo recipient, as described in the text.